Skip to content

The Early Origins of Cardiovascular Disease

The Early Origins of Cardiovascular Disease : the Consequence of Growth Restriction During Foetal Life and Infancy on Cardiovascular Structure and Function in Adulthood

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00923039
Enrollment
200
Registered
2009-06-18
Start date
2009-06-30
Completion date
Unknown
Last updated
2009-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

The early origin of cardiovascular disease

Brief summary

Small body size at birth, slow weight gain during infancy and increase in body mass index after 2 years are independent risk factors for cardiovascular disease and the metabolic syndrome. There is a large gap in our understanding of how early growth affects the cardiovascular system. Possible mechanisms include alterations in body composition, in cardiac structure, in vascular function, in renal function and epigenetic processes. The Objective is to determine how size at birth and growth during infancy and childhood affect: body composition, cardiac structure and function, vascular and endothelial function, renal function, metabolic status and transcriptional and epigenetic characteristics.

Interventions

None listed

Sponsors

Danone Institute International
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* Male and female volunteers students aged between 18-25 years old * Having growth records

Exclusion criteria

* If young women subject without contraception,or pregnant

Design outcomes

Primary

MeasureTime frame
To determine how size at birth and growth during infancy and childhood affect: body composition, cardiac structure and function, vascular and endothelial function, renal function, metabolic status and transcriptional and epigenetic characteristics3 years

Countries

France

Contacts

Primary ContactUmberto SIMEONI, MD,PhD
umberto.simeoni@mail.ap-hm.fr33 (0)4 91 38 40 30
Backup ContactOlivier BLIN, MD,PhD
olivier.blin@mail.ap-hm.fr33 (0)4 91 38 75 63

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026